arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2018-24-1-110-119arthyper-767Research ArticleОРИГИНАЛЬНАЯ СТАТЬЯORIGINAL ARTICLEОСОБЕННОСТИ АНТИГИПЕРТЕНЗИВНОЙ ЭФФЕКТИВНОСТИ НОВОГО ПРЕДСТАВИТЕЛЯ КЛАССА АНТАГОНИСТОВ РЕЦЕПТОРОВ К АНГИОТЕНЗИНУ II — ФИМАСАРТАНА ПРИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ 1–2-Й СТЕПЕНИ: ДОПОЛНИТЕЛЬНЫЙ АНАЛИЗ РЕЗУЛЬТАТОВ ПРЕДРЕГИСТРАЦИОННОГО ИССЛЕДОВАНИЯ В РОССИИNEW ANGIOTENSIN II RECEPTOR BLOCKER FIMASARTAN IN MILD-TO-MODERATE HYPERTENSION: POST-HOC ANALYSIS OF RESULTS OF REGISTRATION TRIAL IN RUSSIAЗвартауН. Э.ZvartauN. E.

Звартау Надежда Эдвиновна — кандидат медицинских наук, руководитель отдела биомедицинских исследований лекарственных средств, руководитель организационно-методического отдела; старший научный сотрудник Института трансляционной медицины.

Санкт-Петербург.

Nadezhda E. Zvartau, MD, PhD, Biomedical Research Department,  Organizational and Methodological Department; Translational Medicine Institute, Senior Researcher. 

Saint-Petersburg.

zvartau@almazovcentre.ruВербицкаяЕ. В.VerbitskayaE. V.

Вербицкая Елена Владимировна — доцент кафедры клинической фармакологии и доказательной медицины, заведующая отделом фармакоэпидемиологии и биомедицинской статистики. 

Санкт-Петербург.

Elena V. Verbitskaya, Department of Clinical Pharmacology and Evidence-based Medicine, Associate Professor; Department of Pharmacoepidemiology and Biostatistics, Head. 

Saint-Petersburg.

ГаланкинТ. Л.GalankinT. L.

Галанкин Тимофей Леонидович — ассистент кафедры клинической фармакологии и доказательной медицины. 

Санкт-Петербург.

Timophei L. Galankin, Department of Clinical Pharmacology and Evidence-based Medicine, Assistant.

Saint-Petersburg.

КонрадиА. О.KonradiA. O.

Конради Александра Олеговна — доктор медицинских наук, профессор, член-корреспондент Российской академии наук, заместитель генерального директора по научной работе;   директор Института трансляционной медицины.

Санкт-Петербург.

Aleksandra O. Konradi, MD, PhD, DSc, Corresponding Member of RAS; the Deputy General Director General of Science;  Translational Medicine Institute, Head.

Saint-Petersburg.

ХозяиноваН. Ю.KhozyainovaN. Yu.

Хозяинова Наталья Юрьевна — доктор медицинских наук, профессор, медицинский советник. 

Москва.

Natalya Yu. Khozyainova, MD, PhD, DSc, Professor, Medical Adviser, Clinical Development & Medical Affairs.

Moscow.

СамсоновМ. Ю.SamsonovM. Yu.

Самсонов Михаил Юрьевич — кандидат медицинских наук, медицинский директор. 

Москва.

Mikhail Yu. Samsonov, MD, PhD, Chief Medical Officer.

Moscow.

Федеральное государственное бюджетное учреждение  «Национальный медицинский исследовательский центр  имени В. А. Алмазова» Министерства здравоохранения  Российской Федерации; Университет ИТМО.РоссияAlmazov National Medical Research Centre; ITMO University.Russian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Первый СанктПетербургский государственный медицинский университет  имени академика И. П. Павлова» Министерства здравоохранения Российской Федерации.РоссияFirst Pavlov State Medical University of Saint-Petersburg.Russian Federation Медицинский департамент, АО «Р-Фарм».РоссияMedical Department, JSC R-Pharm.Russian Federation201812032018241110119Copyright © Звартау Н.Э., Вербицкая Е.В., Галанкин Т.Л., Конради А.О., Хозяинова Н.Ю., Самсонов М.Ю., 20182018Звартау Н.Э., Вербицкая Е.В., Галанкин Т.Л., Конради А.О., Хозяинова Н.Ю., Самсонов М.Ю.Zvartau N.E., Verbitskaya E.V., Galankin T.L., Konradi A.O., Khozyainova N.Y., Samsonov M.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/767артериальная гипертензияантагонисты рецепторов к ангиотензину IIфимасартаножирениедополнительный анализarterial hypertensionangiotensin II receptors antagonistfimasartanobesitypost hoc analysisReferencesQvarnstrom M, Kahan T, Kieler H, Brandt L, Hasselstrom Y, Bostrom K et al. Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol. 2013;69(11): 1955–64. doi:10.1097/MD.0000000000004908Qvarnstrom M, Kahan T, Kieler H, Brandt L, Hasselstrom Y, Bostrom K et al. Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol. 2013;69(11): 1955–64. doi:10.1097/MD.0000000000004908Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–1357. doi:10.1097/01.hjh.0000431740.32696.ccMancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–1357. doi:10.1097/01.hjh.0000431740.32696.ccPaz MA, de-La-Sierra A, Sáez M, Barceló MA, Rodríguez JJ, Castro S et al. Treatment efficacy of anti-hypertensive drugs in monotherapy or combination. ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine. 2016;95(30): e4071. doi:10.1097/MD.0000000000004071Paz MA, de-La-Sierra A, Sáez M, Barceló MA, Rodríguez JJ, Castro S et al. Treatment efficacy of anti-hypertensive drugs in monotherapy or combination. ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine. 2016;95(30): e4071. doi:10.1097/MD.0000000000004071Baguet JP, Robitail S, Boyer L, Debensason D, Auquier P. A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs. 2005;5 (2):131–40.Baguet JP, Robitail S, Boyer L, Debensason D, Auquier P. A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs. 2005;5 (2):131–40.Baguet JP, Legallicier B, Auquier P, Robitail S. Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Clin Drug Investig. 2007;27 (11):735–53.Baguet JP, Legallicier B, Auquier P, Robitail S. Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Clin Drug Investig. 2007;27 (11):735–53.Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess. 2003;7(31):49–58.Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess. 2003;7(31):49–58.Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24h ambulatory blood pressure monitoring. J Hypertens. 2007;25(7):1327–36.Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24h ambulatory blood pressure monitoring. J Hypertens. 2007;25(7):1327–36.Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs. 2008;68(9):1207–25.Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs. 2008;68(9):1207–25.De´zsi CA. The different therapeutic choices with ARBs. Which one to give? When? Why? Am J Cardiovasc Drugs. 2016;16 (4):255–266. doi:10.1007/s40256-016-0165-4De´zsi CA. The different therapeutic choices with ARBs. Which one to give? When? Why? Am J Cardiovasc Drugs. 2016;16 (4):255–266. doi:10.1007/s40256-016-0165-4Звартау Н. Э., Конради А. О., Корнева Е. В., Бессонова Н. А., Болдуева С. А., Егорова Л. П и др. Сравнение антигипертензивной эффективности и безопасности нового представителя класса антагонистов рецепторов к ангиотензину II — фимасартана и лозартана при артериальной гипертензии 1–2-й степени. Артериальная гипертензия. 2016;22 (2):204–216. doi: http://dx.doi.org/10.18705/1607-419X-2016-22-2-204-216 [Zvartau NE, Konradi AO, Korneva EV, Bessonova NA, Boldueva SA, Egorova LP et al. Efficacy and safety of fimasartan, a new angiotensin-receptor blocker, compared to losartan in mild-to-moderate hypertension, Arterial’naya Gipertenziya = Arterial Hypertension. 2016;22(2):204–216. doi: http://dx.doi.org/10.18705/1607-419X-2016-22-2-204-216. In Russian].Звартау Н. Э., Конради А. О., Корнева Е. В., Бессонова Н. А., Болдуева С. А., Егорова Л. П и др. Сравнение антигипертензивной эффективности и безопасности нового представителя класса антагонистов рецепторов к ангиотензину II — фимасартана и лозартана при артериальной гипертензии 1–2-й степени. Артериальная гипертензия. 2016;22 (2):204–216. doi: http://dx.doi.org/10.18705/1607-419X-2016-22-2-204-216 [Zvartau NE, Konradi AO, Korneva EV, Bessonova NA, Boldueva SA, Egorova LP et al. Efficacy and safety of fimasartan, a new angiotensin-receptor blocker, compared to losartan in mild-to-moderate hypertension, Arterial’naya Gipertenziya = Arterial Hypertension. 2016;22(2):204–216. doi: http://dx.doi.org/10.18705/1607-419X-2016-22-2-204-216. In Russian].Keyhani S, Scobie JV, Hebert PL, McLaughlin MA. Gender disparities in blood pressure control and cardiovascular care in a national sample of ambulatory care visits. Hypertension. 2008;51 (4): 1149–55. doi:10.1161/HYPERTENSIONAHA.107.107342Keyhani S, Scobie JV, Hebert PL, McLaughlin MA. Gender disparities in blood pressure control and cardiovascular care in a national sample of ambulatory care visits. Hypertension. 2008;51 (4): 1149–55. doi:10.1161/HYPERTENSIONAHA.107.107342Gu Q, Burt VL, Paulose-Ram R, Dillon CF. Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey1999–2004. Am J Hypertens. 2008;21(7):789–98. doi: 10.1038/ajh.2008Gu Q, Burt VL, Paulose-Ram R, Dillon CF. Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey1999–2004. Am J Hypertens. 2008;21(7):789–98. doi: 10.1038/ajh.2008Journath G, Hellenius ML, Petersson U, Theobald H, Nilsson PM, Hyper QSGS. Sex differences in risk factor control of treated hypertensives: a national primary healthcare-based study in Sweden. Eur J Cardiovasc Prevent Rehabil. 2008;5(3):258–62. doi:https://doi.org/10.1097/HJR.0b013e3282f37a45Journath G, Hellenius ML, Petersson U, Theobald H, Nilsson PM, Hyper QSGS. Sex differences in risk factor control of treated hypertensives: a national primary healthcare-based study in Sweden. Eur J Cardiovasc Prevent Rehabil. 2008;5(3):258–62. doi:https://doi.org/10.1097/HJR.0b013e3282f37a45Ljungman C, Kahan T, Schiöler L, Hjerpe P, Hasselström J, Wettermark B et al. Gender differences in antihypertensive drug treatment: results from the Swedish Primary Care Cardiovascular Database (SPCCD). J Am Soc Hypertens. 2014;8(12):882–90. doi:10.1016/j.jash.2014.08.015Ljungman C, Kahan T, Schiöler L, Hjerpe P, Hasselström J, Wettermark B et al. Gender differences in antihypertensive drug treatment: results from the Swedish Primary Care Cardiovascular Database (SPCCD). J Am Soc Hypertens. 2014;8(12):882–90. doi:10.1016/j.jash.2014.08.015Kim S, Joo S, Shin M, Kim C, Cho E, Sung K et al. Clinic and home blood pressure lowering effect of an angiotensin receptor blocker, fimasartan, in postmenopausal women with hypertension. Medicine. 2016;95(22): e3764. doi:10.1097/MD.0000000000003764Kim S, Joo S, Shin M, Kim C, Cho E, Sung K et al. Clinic and home blood pressure lowering effect of an angiotensin receptor blocker, fimasartan, in postmenopausal women with hypertension. Medicine. 2016;95(22): e3764. doi:10.1097/MD.0000000000003764Lima R, Wofford M, Reckelhoff JF. Hypertension in postmenopausal women. Curr Hypertens Rep. 2012;14(3):254–260. doi:10.1007/s11906-012-0260-0Lima R, Wofford M, Reckelhoff JF. Hypertension in postmenopausal women. Curr Hypertens Rep. 2012;14(3):254–260. doi:10.1007/s11906-012-0260-0Yanes LL, Romero DG, Iliescu R, Zhang H, Davis D, Reckelhoff J. Postmenopausal hypertension: role of the reninangiotensin system. Hypertension. 2010;56(3):359–363. doi:10.1161/HYPERTENSIONAHA.110.152975Yanes LL, Romero DG, Iliescu R, Zhang H, Davis D, Reckelhoff J. Postmenopausal hypertension: role of the reninangiotensin system. Hypertension. 2010;56(3):359–363. doi:10.1161/HYPERTENSIONAHA.110.152975Shin M, Kang D, Kim C, Cho E, Sung K, Kanget S et al. Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension. Drug Design, Develop Ther. 2016;10:1573–1580. doi:10.2147/DDDT.S107433Shin M, Kang D, Kim C, Cho E, Sung K, Kanget S et al. Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension. Drug Design, Develop Ther. 2016;10:1573–1580. doi:10.2147/DDDT.S107433Kato T, Kikuya M, Ohkubo T, Satoh M, Hara A, Obara T et al. Factors associated with day-by-day variability of self-measured blood pressure at home: the Ohasama study. Am J Hypertens. 2010;23(9):980–986. doi:https://doi.org/10.1038/ajh.2010.94Kato T, Kikuya M, Ohkubo T, Satoh M, Hara A, Obara T et al. Factors associated with day-by-day variability of self-measured blood pressure at home: the Ohasama study. Am J Hypertens. 2010;23(9):980–986. doi:https://doi.org/10.1038/ajh.2010.94Mallion J, Siche J, Lacourciere Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild to moderate hypertension. J Hum Hypertens. 1999;13(10):657–664.Mallion J, Siche J, Lacourciere Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild to moderate hypertension. J Hum Hypertens. 1999;13(10):657–664.de la Sierra A, Banegas JR, Oliveras A, Gorostidi M, Segura J, de la Cruz JJ et al. Clinical differences between resistant hypertensive patients and patients treated and controlled with three or less drugs. J Hypertens. 2012;30(6):1211–6. doi:10.1097/HJH.0b013e328353634ede la Sierra A, Banegas JR, Oliveras A, Gorostidi M, Segura J, de la Cruz JJ et al. Clinical differences between resistant hypertensive patients and patients treated and controlled with three or less drugs. J Hypertens. 2012;30(6):1211–6. doi:10.1097/HJH.0b013e328353634eИвашкин В. Т., Драпкина О. М., Маев В. С., Трухманов С., Блинов Д. В., Пальгова Л. К. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;25 (56):31–38. [Ivashkin VT, Drapkina OM, Maev VS, Truhmanov S, Blinov DV, Palgova LK et al. Prevalence of non-alcoholic fatty liver disease in out-patient setting in Russia: results of DIREG 2 study. Rossiyiskyi Zhurnal Gastroenterologii, Hepatologii, Coloproctologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(56):31–38. In Russian].Ивашкин В. Т., Драпкина О. М., Маев В. С., Трухманов С., Блинов Д. В., Пальгова Л. К. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;25 (56):31–38. [Ivashkin VT, Drapkina OM, Maev VS, Truhmanov S, Blinov DV, Palgova LK et al. Prevalence of non-alcoholic fatty liver disease in out-patient setting in Russia: results of DIREG 2 study. Rossiyiskyi Zhurnal Gastroenterologii, Hepatologii, Coloproctologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(56):31–38. In Russian].Драпкина О. М., Елиашевич С. О., Шепель Р. Н. Ожирение как фактор риска хронических неинфекционных заболеваний. Российский кардиологический журнал. 2016; (6):73–79. doi:10.15829/1560-4071-2016-6-73-79 [Drapkina OM, Eliashevich SO, Shepel RN. Obesity as a risk factor for chronic noninfectious diseases. Russian Journal of Cardiology. 2016;(6):73–79. doi:10.15829/1560-4071-2016-6-73-79. In Russian].Драпкина О. М., Елиашевич С. О., Шепель Р. Н. Ожирение как фактор риска хронических неинфекционных заболеваний. Российский кардиологический журнал. 2016; (6):73–79. doi:10.15829/1560-4071-2016-6-73-79 [Drapkina OM, Eliashevich SO, Shepel RN. Obesity as a risk factor for chronic noninfectious diseases. Russian Journal of Cardiology. 2016;(6):73–79. doi:10.15829/1560-4071-2016-6-73-79. In Russian].Lee Y, Jang Y, Han Y et al. Fimasartan ameliorates nonalcoholic fatty liver disease through PPAR and regulation in hyperlipidemic and hypertensive conditions. PPAR Res. 2017: Article ID 8048720: http://dx.doi.org/10.1155/2017/8048720.Lee Y, Jang Y, Han Y et al. Fimasartan ameliorates nonalcoholic fatty liver disease through PPAR and regulation in hyperlipidemic and hypertensive conditions. PPAR Res. 2017: Article ID 8048720: http://dx.doi.org/10.1155/2017/8048720.

The authors declare that there are no conflicts of interest present.